Copied
 
 
Formål
Formål
Selskabets formål er at drive virksomhed ved forskning, udvikling og handel indenfor biotek og anden hermed beslægtet virksomhed.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 27.05.2010 (5324 dage).
Ingen historik.
Status
Virksomhedsstatus
NORMAL.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 18.12.2006 (6580 dage).
Ingen historik.
Branche
Branche
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900).
Sidst opdateret den 24.12.2007 og angivet som gældende fra 01.01.2008 (6201 dage).
HistorikStartStop
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)01.01.2008
Forskning og udvikling inden for naturvidenskab og teknik (731000)18.12.200631.12.2007
Revision
Revisionfravalgt
false.
Sidst opdateret den 11.03.2015 og angivet som gældende fra 18.12.2006 (6580 dage).
Ingen historik.
Revisor
Revisor
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB
Sidst opdateret den 09.02.2015 og angivet som gældende fra 13.10.2011 (4820 dage).
Form
Virksomhedsform
80.
Sidst opdateret den 05.03.2007 og angivet som gældende fra 18.12.2006 (6580 dage).
Ingen historik.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Telefonnummer
20181111.
Sidst opdateret den 09.04.2015 og angivet som gældende fra 09.04.2015 (3546 dage).
Ingen historik.
Navne
Binavne
Binavne
Heat Shock Therapeutics ApS.
Sidst opdateret den 03.09.2024 og angivet som gældende fra 03.09.2024 (111 dage).
HistorikStartStop
Heat Shock Therapeutics ApS03.09.2024
Drug Delivery Solutions ApS18.03.2021
PAD Technology ApS18.03.2021
Wynzora ApS18.03.2021
MC2 DELIVERY ApS18.12.200617.03.2021
Tegningsregel
Tegningsregel
Selskabet tegnes af direktøren.
Sidst opdateret den 09.02.2015 og angivet som gældende fra 27.05.2010 (5324 dage).
Fortolkning (1 tegningsmulighed)
direktøren
Ingen historik.
Ansatte
23.12.2024
Ingen historik.
Kapital
23.12.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Biomee ApS for the financial year 01. 01. 2023 - 31. 12. 2023, which comprise the income statement, balance sheet, statement of changes in equity and ​notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. ​ ​In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31. 12. 2023 and of the results of its operations for the financial year 01. 01. 2023 - 31. 12. 2023 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the management commentary. Our opinion on the financial statements døs not cover the management commentary, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
23.12.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
23.12.2024
Ingen nuværende registrering.
Ingen historik.